Periodic benefit-risk evaluation reports have substantial promise to guide patient care and should be made publicly available

Pharmacoepidemiol Drug Saf. 2017 May;26(5):597-599. doi: 10.1002/pds.4177. Epub 2017 Feb 15.

Authors

Michael Fralick^{1

2}, Aaron S Kesselheim¹

Affiliations

¹ Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvarde Medical School, Boston, MA, USA.
² University of Toronto Clinician-Scientist Program, Toronto, ON, Canada.

PMID: 28198116
DOI: 10.1002/pds.4177

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Disclosure*
Drug Approval
Drug-Related Side Effects and Adverse Reactions / epidemiology*
Humans
Patient Care / standards*
United States
United States Food and Drug Administration